Avodart® is the new medication
from GlaxoSmithKline for reducing DHT. Dihydrotestosterone (DHT)
is the main hormone linked to hairloss. Propecia® prevents
one of two enzymes from being converted into DHT and blocks 2/3
of the DHT production. The new medication Avodart® blocks
both enzymes in the body that convert into DHT and reduces overall
DHT production by over 93%.
Avodart® comes in a 0.5mg
softgel capsule that is taken by mouth once per day.
Propecia was originally approved
under the name Proscar® for BPH and was only released for
hair loss years later. Avodart has been approved for the treatment
of Benign Prostatic Hyperplasia (BPH, or enlarged prostates) and
is currently under study for approval for hair loss.
Avodart® at this dosage reduced
DHT by 93.1-93.6% after 12-months on the medication. Scalp DHT
was decreased 38% for Propecia®/Finasteride compared to 54%
for 0.5mg Dutasteride.
Since Avodart® is currently
being studied for hair loss, there are no exact figures on the
percent of responders or results other than some of the sample
photos released by the company from the studies. Results are expected
to surpass Propecia's.
Our Avodart® is the original
brand-name Avodart® 0.5mg from GlaxoSmithKline in the United
States and is not a generic or international formulation.
Avodart® is not tested or
approved for women and should not under any circumstances be taken
by women who may become pregnant.
your life a better life Contact the Better Life Group designed
and hosted by blue